Can maraviroc help HIV patients whose immune systems lag behind?
NCT ID NCT00944541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug maraviroc to standard HIV treatment could help improve immune function in people whose CD4 counts remain low even when the virus is well-controlled. It involved 60 HIV-positive adults with low CD4 counts and little recent immune improvement. Participants took maraviroc for 24 weeks, and researchers monitored their immune recovery and safety for up to 48 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
French National Agency for Research on AIDS and Viral Hepatits
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?